# Cartilage repair Mesa choices begin with simpler care *A Simple Care Guide | Cartilage Repair Mesa* > Cartilage repair Mesa choices cover daily care, non-surgical relief, and surgery for certain cartilage damage. This page covers home care, non-surgical relief, and surgery for cartilage damage. Care often begins with changes that reduce strain. Your exam, scan, and daily limits help decide what comes next. One damaged spot is different from wear spread across the joint. The choice depends on the kind of damage. ## Home care reduces strain on the joint Shorter walks, level routes, and a rest between chores may reduce a flare. Strong leg muscles can take some strain from a sore knee or hip. Some people do better with a fitted cane or brace, and a therapist can help select the right support. Should you keep moving? Usually, yes, unless activity brings sharp pain or swelling that lasts. You don't have to push through a bad day. Choose an effort that leaves the joint nearly back to normal the next morning. Medicine may ease soreness, though it isn't safe for every health history. Ask how it may mix with medicines you already take. Comfort the joint without making tomorrow harder. ## Non-surgical care aims to ease soreness and improve movement Concentrated platelet-rich plasma (PRP) is among QC Kinetix's non-surgical options; staff draw your blood, gather more platelets together, then place them in the sore joint. A health review and joint exam come before any care is discussed. A scan can't tell how much relief you may feel. Surgery may suit one deep, clearly marked damaged spot. A graft fills that spot with a plug from a quieter part of the same knee or with donor tissue. Joint replacement is meant for wear spread across much of the joint, and QC Kinetix doesn't perform either operation. Healing from graft surgery takes months, with early limits on walking or driving. A surgeon checks whether the damage suits an operation. If it doesn't, home care or non-surgical care may still ease soreness. A small damaged spot and broad wear call for different choices. ## Sources 1. A JBJS evidence-based review of chondral lesions of the knee sets management by lesion size, location, limb alignment and rotation, and patient demand rather than by product: osteochondral autograft transfer is described as durable and predictable for smaller lesions (under 2 cm2) in young active patients, while lesions of 2 cm2 or more are typically treated with osteochondral allograft transplantation, particulated juvenile articular cartilage, or matrix-associated chondrocyte implantation, with favourable mid- and long-term results reported for allograft or MACI in large lesions of 3 cm2 or more. Dekker TJ, et al. — [Chondral Lesions of the Knee: An Evidence-Based Approach.](https://pubmed.ncbi.nlm.nih.gov/33470591/). *J Bone Joint Surg Am*, 2021. DOI: 10.2106/JBJS.20.01161. 2. Carbon-14 bomb-pulse dating of tibial plateau cartilage from 23 people born between 1935 and 1997 showed that virtually no replacement of the cartilage collagen matrix happens after skeletal maturity, and that neither osteoarthritis nor tissue damage changed that turnover rate. This is the measurement behind the statement that adult articular cartilage has almost no capacity for self-repair. Heinemeier KM, et al. — [Radiocarbon dating reveals minimal collagen turnover in both healthy and osteoarthritic human cartilage.](https://pubmed.ncbi.nlm.nih.gov/27384346/). *Sci Transl Med*, 2016. DOI: 10.1126/scitranslmed.aad8335. 3. A 251-patient multicentre randomised trial deliberately enrolled knees with concurrent mild to moderate osteoarthritis (Kellgren-Lawrence 0-3) alongside focal defects of 1 to 7 cm2. An aragonite-based osteochondral implant beat arthroscopic debridement and microfracture on the primary endpoint and every secondary endpoint: 77.8% versus 33.6% responders at two years, at least 75% MRI defect fill in 88.5% versus 30.9%, and failure in 7.2% versus 21.4%. Altschuler N, et al. — [Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial.](https://pubmed.ncbi.nlm.nih.gov/36779614/). *Am J Sports Med*, 2023. DOI: 10.1177/03635465231151252. 4. In the RESTORE randomised trial, 288 people aged 50 or over with symptomatic mild-to-moderate medial knee osteoarthritis received three weekly injections of leukocyte-poor PRP or saline placebo. At 12 months there was no significant difference in knee pain (-2.1 versus -1.8 points) and none in medial tibial cartilage VOLUME (-1.4% versus -1.2%). Twenty-nine of 31 prespecified secondary outcomes also showed no difference. Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 5. FDA's consumer alert states verbatim of stem cell products, exosome products, adipose-derived stromal vascular fraction, umbilical cord blood, Wharton's Jelly and amniotic fluid products: "None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain." The only stem cell products carrying FDA licensure are blood-forming cells derived from umbilical cord blood, licensed only for disorders of blood production, and there are currently no licensed exosome products. U.S. Food and Drug Administration — [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). *FDA, Consumers (Biologics)*, 2020. 6. In 70 knees treated with particulated juvenile articular cartilage for full-thickness patellar defects, all patient-reported outcome scores improved significantly by two years (IKDC 41.1 to 73.5, Kujala 52 to 86.3). MRI showed defect fill above 66% in most patients by three months - and there was NO association between the percentage of defect fill and the outcome scores at one or two years. Marmor WA, et al. — [Outcomes of Particulated Juvenile Articular Cartilage and Association With Defect Fill in Patients With Full-Thickness Patellar Chondral Lesions.](https://pubmed.ncbi.nlm.nih.gov/39045351/). *Orthop J Sports Med*, 2024. DOI: 10.1177/23259671241249121. 7. The first long-term randomised comparison of autologous chondrocyte implantation with mosaicplasty followed 100 patients with large lesions (mean about 4 cm2) for a minimum of ten years. Failure had occurred in 10 of 58 ACI patients (17%) versus 23 of 42 mosaicplasty patients (55%), and functional outcome among surviving grafts was significantly better after ACI. Bentley G, et al. — [Minimum ten-year results of a prospective randomised study of autologous chondrocyte implantation versus mosaicplasty for symptomatic articular cartilage lesions of the knee.](https://pubmed.ncbi.nlm.nih.gov/22434467/). *J Bone Joint Surg Br*, 2012. DOI: 10.1302/0301-620X.94B4.27495. ## Talk through the soreness with the clinic team Bring prior reports and describe how the soreness started. The clinic team can review non-surgical options and explain if a different visit may be needed. Call (602) 837-PAIN to speak with the team. Talk to the clinic team: --- Clear answers about cartilage soreness and the care available near Mesa. Cartilage repair Mesa guidance on why joints ache, steps you can take at home, reasons to seek care, and local options. Plain guidance about cartilage soreness, care choices, and nearby clinic access. This site is run by the owners and operators of the QC Kinetix clinics serving the Phoenix area; its appointment links lead to their clinic group, while the source deck lets readers inspect the evidence used in each editorial chapter. Copyright 2026 Mesa Cartilage Field Notes. General education only; a clinician who examines your joint must make diagnosis and care decisions.